Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-I/parathyroid hormone axis

Prostate

Volumn 70, Issue 2, 2010, Pages 155-161

  Isahaya, Etsuko ^a   Hara, Noboru ^a   Nishiyama, Tsutomu ^a   Hoshii, Tatsuhiko ^a   Takizawa, Itsuhiro ^a   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Androgen deprivation therapy; Bone metabolism; Insulin like growth factor 1

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; FLUTAMIDE; GOSERELIN; GROWTH HORMONE; PARATHYROID HORMONE; PHOSPHORUS; SOMATOMEDIN C;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE METABOLISM; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSSIFICATION; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; URINALYSIS;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BONE DISEASES, METABOLIC; FLUTAMIDE; GOSERELIN; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; ORCHIECTOMY; PARATHYROID HORMONE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 73449103209     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21047     Document Type: Article

References (22)

1. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin 2008;58:196-213.
2. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410-6417.
3. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90:657-660.
4. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955.
5. Stoch SA, Parker RA, Chen L, Bubley G, Ko Y-J, Vincelette A, Greenspan SL. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001;86:2787-2791.
6. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. A randomized trial. Ann Intern Med 2007;146:416-424.
7. Townsend MF, Sanders WH, Northway RO, Graham SDJ. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer 1997;79:545-550.
8. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164.
9. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: Aclaims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897-7903.
10. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989;10:68-91.
11. Kamel HK. Growth hormone/insulin-like growth factor-1/PTH axis in bone. Drugs Aging 2005;22:741-748.
12. Léger J, Mercat I, Alberti C, Chevenne D, Armoogum P, Tichet J, Czernichow P. The relationship between the GH/IGF-I axis and serum markers of bone turnover metabolism in healthy children. Eur J Endocrinol 2007;157:685-692.
13. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008;29:535-559.
14. Agnusdei D, Gentilella R. GH and IGF-I as therapeutic agents for osteoporosis. J Endocrinol Invest 2005;28:32-36.
15. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: A practical review and guide for the clinician. Urol Clin North Am 2004;31:331-352.
16. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF. Growth hormone(GH) receptor blockade with a PEG-modifiedGH(B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 1999;84:2098-2103.
17. Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, Schröder FH. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: Results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 2004;89:4391-4396.
18. Anawalt BD, Merriam GR. Neuroendocrine aging in men. Andropause and somatopause. Endocrinol Metab Clin North Am 2001;30:647-669.
19. Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Lombardi G, Tauchmanova L, Di Somma C, Musella T, Rota F, Savanelli MC, Colao A. Somatopause: Dismetabolic and bone effects. J Endocrinol Invest 2005;28(10 Suppl):36-42.
20. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004; 25:389-425.
21. Gutiérrez S, Mukdsi JH, Aoki A, Torres AI, Soler AP, Orgnero EM. Ultrastructural immunolocalization of IGF-1 and insulin receptors in rat pituitary culture: Evidence of a functional interaction between gonadotroph and lactotroph cells. Cell Tissue Res 2007;327:121-132.
22. Huang YS, Rousseau K, Le Belle N, Vidal B, Burzawa-Gérard E, Marchelidon J, Dufour S. Insulin-like growth factor-I stimulates gonadotrophin production from eel pituitary cells: A possible metabolic signal for induction of puberty. J Endocrinol 1998; 159:43-52.